OakChart

Kymera Therapeutics Inc

KYMRHealthcare·Biotechnology·USA·Large·NASD·Nov 11 • 11:16 AM ET

135.70-0.94 (-0.69%)
2026-11-11 17:16 CET
Market cap
11,665.15 USD m
Revenue, TTM
102.23 USD m
Net income, TTM
-349.43 USD m
Free cash flow, TTM
-288.89 USD m
EPS diluted, TTM
-3.62
P/E
-
Compare

Price

KYMR against its 20, 50 and 200-day averages
2050200beatmiss
80.00100.00120.00140.002.1M4.3MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26KYMRclose 135.7020-day 121.7450-day 116.77200-day 98.90135.7052w high

5.1% under the 52-week high of 142.92 on 10 Nov 2026. 52-week low 60.25 on 11 Nov 2025. Last 15 sessions, 31.1% high to low

Profile

KYMR
52-week range, 91% of the way up
60.25142.92

Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of human diseases through the development of innovative, highly differentiated medicines. It focuses on discovering and developing novel small-molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's natural protein degradation system. The company leverages targeted protein degradation (TPD) to develop medicines that address critical health challenges and have the potential to significantly improve patients lives. Its pipeline emphasizes oral small-molecule degraders, offering a new generation of convenient and highly effective therapies. The company was founded by Bruce Lee Booth and Nello Mainolfi on September 29, 2015 and is headquartered in Watertown, MA.

IndexRUT
Employees238
IPOAug 21, 2020
Beta2.02
ATR, 14d6.76
Rel volume0.55
Short float10.96%
Insider own10.18%
Inst own106.70%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap11.58B
Enterprise Value10.69B
Income-349.43M
Sales102.23M
Book/sh18.92
Cash/sh11.38
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees238
IPOAug 21, 2020

Ratios

P/E-
Forward P/E-
PEG-
P/S113.32
P/B7.17
P/C11.93
P/FCF-
EV/EBITDA-
EV/Sales104.57
Quick Ratio11.13
Current Ratio11.13
Debt/Eq0.05
LT Debt/Eq0.04
Option/ShortYes / Yes

Earnings

EPS (ttm)-3.62
EPS next Y-5.13
EPS next Q-1.29
EPS this Y-6.98%
EPS next Y-29.95%
EPS next 5Y-15.07%
EPS past 3/5Y-8.68% -3.19%
Sales past 3/5Y-5.74% 2.87%
EPS Y/Y TTM-0.64%
Sales Y/Y TTM133.77%
EPS Q/Q-40.09%
Sales Q/Q-100.00%
EarningsOct 29 BMO
EPS/Sales Surpr.-4.37% -100.00%

Ownership

Insider Own10.18%
Insider Trans-29.54%
Inst Own106.70%
Inst Trans-0.22%
ROA-24.36%
ROE-27.29%
ROIC-20.83%
Gross Margin92.07%
Oper. Margin-396.04%
Profit Margin-341.79%
SMA2011.47%
SMA5016.21%
SMA20037.21%
Trades-

Technical

Shs Outstand85.33M
Shs Float76.68M
Short Float10.96%
Short Ratio9.82
Short Interest8.40M
52W High142.92 -5.05%
52W Low60.25 125.23%
Volatility7.35% 5.64%
ATR (14)6.76
RSI (14)65.74
Beta2.02
Rel Volume0.55
Avg Volume855.68K
Volume145,152

Performance

Perf Week-0.40%
Perf Month27.20%
Perf Quarter18.60%
Perf Half Y58.55%
Perf YTD74.40%
Perf Year114.14%
Perf 3Y834.57%
Perf 5Y114.72%
Perf 10Y-
Recom1.25
Target Price145.22
Prev Close136.64
Price135.70
Change %-0.69%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 09, 2026InitiatedRRaymond JamesOutperform$140+3.2%
Sep 10, 2026UpgradeWWolfe ResearchPeer Perform → Outperform$180+32.6%
Jul 30, 2026InitiatedDDeutsche BankHold$120-11.6%
May 06, 2026InitiatedCCanaccord GenuityBuy$106-21.9%
Mar 16, 2026ResumedJJefferiesBuy
Jan 28, 2026ResumedBBarclaysOverweight$133-2.0%
Jan 06, 2026DowngradeWWolfe ResearchOutperform → Peer Perform
Nov 03, 2025ResumedGGuggenheimBuy$90-33.7%
Oct 24, 2025ReiteratedRB. Riley SecuritiesBuy$60 → $80-41.0%
Oct 21, 2025InitiatedMMizuhoOutperform$81-40.3%

Peers

Mkt cap
TickerCompanyMkt cap
NRIXNurix Therapeutics Inc1.79B
GLUEMonte Rosa Therapeutics Inc884.84M
ARVNArvinas Inc449.28M
REGNRegeneron Pharmaceuticals Inc94.67B
PTGXProtagonist Therapeutics Inc8.71B
CCCCC4 Therapeutics Inc393.95M
ODTXOdyssey Therapeutics Inc983.95M
ALMSAlumis Inc879.07M
ATTOAttovia Therapeutics Inc779.19M
SNYSanofi ADR114.13B

Insider trading

latest 14 of 100
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Mainolfi NelloChief Executive OfficerOct 01 '26Option Exercise2.0830,00062,400696,568Oct 01 05:20 PM
Mainolfi NelloChief Executive OfficerOct 01 '26Sale113.8030,0003,413,917666,568Oct 01 05:20 PM
Mainolfi NelloOfficerOct 01 '26Proposed Sale111.7930,0003,353,700Oct 01 04:10 PM
Adams BrianChief Legal OfficerSep 04 '26Sale116.836,371744,29750,254Sep 04 06:00 PM
Brian AdamsOfficerSep 04 '26Proposed Sale117.286,371747,191Sep 04 04:15 PM
JEREMY CHADWICKOfficerSep 02 '26Proposed Sale119.0510,8791,295,145Sep 02 04:32 PM
Mainolfi NelloChief Executive OfficerJul 07 '26Option Exercise2.0850,000104,000716,568Jul 07 08:00 PM
Mainolfi NelloChief Executive OfficerJul 07 '26Sale119.0050,0005,950,000666,568Jul 07 08:00 PM
Mainolfi NelloOfficerJul 07 '26Proposed Sale119.0050,0005,950,000Jul 07 04:07 PM
Jacobs Bruce N.Chief Financial OfficerJun 30 '26Option Exercise5.3361,378327,145321,992Jul 02 06:30 PM
Jacobs Bruce N.Chief Financial OfficerJun 30 '26Sale114.9677,1098,864,829244,883Jul 02 06:30 PM
Goodman NoahChief Business OfficerJul 01 '26Sale114.293,389387,32947,179Jul 02 06:30 PM
Mainolfi NelloChief Executive OfficerJul 01 '26Option Exercise2.0880,000166,400746,568Jul 02 06:30 PM
Mainolfi NelloChief Executive OfficerJul 01 '26Sale115.2980,0009,223,527666,568Jul 02 06:30 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VBVanguard Morningstar Small-Cap ETFAUM: 79.59B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
VBKVanguard Morningstar Small-Cap Growth ETFAUM: 22.34B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IBBiShares Biotechnology ETFAUM: 11.36B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B

News

latest 14 of 206
  • Kymera Misses On A Revenue-Free Quarter, But KT-579 Data And An On-Track KT-621 Readout Keep The Focus On Year-End (Earnings Whispers)
  • Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial (GlobeNewswire)
  • Kymera Therapeutics to Announce KT-579 Phase 1 Healthy Volunteer Trial Results on October 29, 2026 (GlobeNewswire)
  • Kymera Heads Into Quarter With Revenue Pause As Year-End Eczema Readout Looms (Earnings Whispers)
  • Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026 (GlobeNewswire)
  • Loading…
  • Big Pharma Is Pouring Billions Into a New Class of 'Protein Degrader' Drugs (The Wall Street Journal)
  • Kymera Therapeutics to Participate in Upcoming September Investor Conferences (GlobeNewswire)
  • Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses (GlobeNewswire)
  • Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update (GlobeNewswire)
  • Earnings To Watch: Kymera Therapeutics Inc (KYMR) Q2 2026 -- GF Value Sees 80% Downside (GuruFocus.com)
  • Humana upgraded, Las Vegas Sands downgraded: Wall Street's top analyst calls (The Fly)
  • Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026 (GlobeNewswire)
  • Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-10-29-1.320-1.265-1.3200.003.2823
2026Q22026-08-05-0.620-0.713-0.62465.0032.7823
2026Q12026-04-30-0.710-0.881-0.71034.378.2720
2025Q42026-02-26-0.970-0.784-0.9672.8715.0522
2025Q32025-11-04-0.940-0.770-0.9412.7621.9623
2025Q22025-08-11-0.950-0.810-0.95211.4822.2419
2025Q12025-05-09-0.820-0.907-0.81822.1010.7317
2024Q42025-02-27-0.880-0.775-0.8857.3914.3620
2024Q32024-10-31-0.820-0.832-0.8213.7410.3417
2024Q22024-08-07-0.580-0.681-0.57625.6512.5516
2024Q12024-05-02-0.690-0.721-0.68610.2914.2414
2023Q42024-02-22-0.250-0.404-0.24647.8841.9416
2023Q32023-11-02-0.900-0.637-0.9054.7315.9716
2023Q22023-08-03-0.670-0.636-0.66516.5114.0616
2023Q12023-05-04-0.700-0.684-0.7039.5014.1514
2022Q42023-02-23-0.600-0.630-0.60216.1022.0516

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-3.150-1.437-3.15034.0042.01
2021FY-2.090-1.865-2.08872.8383.71
2022FY-2.870-2.898-2.87046.8050.19
2023FY-2.520-2.643-2.51878.5969.37
2024FY-2.980-2.821-2.98347.0753.87
2025FY-3.690-3.449-3.69039.2153.89
2026FY--3.947--100.48
2027FY--5.130--42.03
2028FY--5.622--41.64
2029FY--6.041--73.89
2030FY--4.772--354.96

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-10-2918041.23-1.0010.00
2026Q4S2026-10-2818003.70-1.0020.00
2026Q4S2026-10-2119004.29-1.0020.00
2026Q4S2026-10-1919014.29-1.0020.00
2026Q4S2026-10-0519184.29-1.0020.00
2026Q4S2026-09-2318184.22-1.0020.00
2026Q4S2026-09-1617184.46-1.0020.00
2026Q4S2026-09-0418185.33-1.0020.00
2026Q4S2026-08-0819195.70-1.0020.00
2026Q4S2026-08-0720195.92-1.0020.00
2026Q4S2026-08-0520286.88-1.0020.00
2026Q4S2026-07-28201210.33-1.0037.80
2026Q4S2026-07-16191210.71-1.0037.80
2026Q4S2026-07-15192110.74-1.0037.80

Estimate history

EPS, annual-0.482-0.926-3.15-2.088-2.87-2.518-2.983-3.685-3.6194
Period20182019202020212022202320242025TTM
EPS, quarterly-0.821-0.885-0.818-0.952-0.941-0.967-0.71-0.624-1.319
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual02.93434.03472.83246.82678.59247.07239.211102.23
Period20182019202020212022202320242025TTM
Sales, quarterly3.7417.39422.111.4762.7642.8734.365650
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual44.5344.5344.48251.53655.03955.58564.8981.32485.326
Period20182019202020212022202320242025MRQ
Shares, quarterly64.74864.8965.11370.55771.74181.32482.18282.78885.326
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue102.2339.2147.0778.5946.8372.8334.032.930.00
Cost of Goods Sold Incl. D&A8.118.317.373.562.982.40-0.820.20
Gross Profit94.1330.9039.7075.0343.8570.44-2.11-0.20
Selling, General and Administrative Excl. Other499.02376.44296.41240.56205.10170.9778.5844.3121.25
Research and Development421.88308.25232.88185.52161.27134.6260.3437.1617.68
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-404.89-345.54-256.71-165.53-161.26-100.53-46.30-42.20-21.45
Interest Expense0.290.370.250.200.180.170.120.050.02
Unusual Expense0.003.854.920.000.000.000.000.000.00
Net Income Before Taxes-349.43-311.35-223.86-146.96-154.81-100.22-45.59-41.25-21.47
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-349.43-311.35-223.86-146.96-154.81-100.22-45.59-41.25-21.47
Net Income From Continuing Operations-349.43-311.35-223.86-146.96-154.81-100.22-45.59-41.25-21.47
Net Income-349.43-311.35-223.86-146.96-154.81-100.22-54.64-41.25-21.47
EPS (Recurring)-3.49-3.65-2.94-2.52-2.87-2.09-3.15-0.93-0.48
EPS (Basic, Before Extraordinaries)-3.62-3.69-2.98-2.52-2.87-2.09-3.15-0.93-0.48
EPS (Diluted)-3.62-3.69-2.98-2.52-2.87-2.09-3.15-0.93-0.48
EBITDA-396.78-337.23-249.34-161.97-158.28-98.13-44.54-41.38-21.25
Non-Operating Income (Expense)55.7638.4238.0318.766.620.490.831.000.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense68.2359.9055.0143.1235.4824.975.191.200.65
Price To Sales Ratio109.45167.6664.1418.9128.7541.8331.61--
Gross Margin92.0778.8084.3495.4693.6496.71-71.88-
Operating Margin-396.04-881.24-545.36-210.62-344.37-138.03-136.05-1,438.48-
Net Margin-341.79-794.04-475.57-186.99-330.60-137.60-160.55-1,405.79-
Shares Outstanding85.3381.3264.8955.5955.0451.5444.4844.5344.53
Market Capitalization11,665.1511,665.152,605.511,412.711,369.423,262.572,756.453,194.37-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.0065.0034.372.872.7611.4822.107.39
Cost of Goods Sold Incl. D&A2.022.032.022.032.152.082.051.97
Gross Profit-2.0262.9732.340.840.619.3920.055.42
Selling, General and Administrative Excl. Other145.21138.58116.5098.7389.2893.9594.4886.18
Research and Development126.49117.4596.1481.8071.9476.3078.2169.84
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-147.23-75.61-84.15-97.90-88.67-84.56-74.43-80.75
Interest Expense0.060.080.060.090.100.110.070.06
Unusual Expense0.000.000.000.003.850.000.000.00
Net Income Before Taxes-132.00-61.21-69.23-86.98-82.17-76.61-65.58-70.75
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-132.00-61.21-69.23-86.98-82.17-76.61-65.58-70.75
Net Income From Continuing Operations-132.00-61.21-69.23-86.98-82.17-76.61-65.58-70.75
Net Income-132.00-61.21-69.23-86.98-82.17-76.61-65.58-70.75
EPS (Recurring)-1.32-0.62-0.71-0.97-0.91-0.95-0.82-0.88
EPS (Basic, Before Extraordinaries)-1.32-0.62-0.71-0.97-0.94-0.95-0.82-0.88
EPS (Diluted)-1.32-0.62-0.71-0.97-0.94-0.95-0.82-0.88
EBITDA-145.21-73.58-82.13-95.86-86.52-82.47-72.38-78.78
Non-Operating Income (Expense)15.2914.4814.9811.0110.448.058.9210.06
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense18.8418.9416.0114.4515.8015.4114.2313.80
Price To Sales Ratio109.45107.22157.82178.43112.9878.5237.2568.36
Gross Margin-96.8894.1229.2022.2581.8490.7373.32
Operating Margin--116.32-244.88-3,411.01-3,207.89-736.82-336.77-1,092.17
Net Margin--94.17-201.47-3,030.70-2,973.05-667.60-296.75-956.88
Shares Outstanding85.3382.7982.1881.3271.7470.5665.1164.89
Market Capitalization11,665.159,432.486,800.006,143.024,046.762,841.821,777.522,605.51

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments848.28488.74374.88407.17442.42296.2091.9641.26
Short Term Receivables0.000.9518.762.540.141.430.000.15
Inventories0.000.000.000.000.000.000.000.00
Other Current Assets22.9420.5811.679.718.724.700.890.38
Total Current Assets871.21510.27405.32419.42451.27302.3492.8441.79
Net Property, Plant & Equipment85.5397.86101.0822.2421.3120.6922.082.24
Total Investments and Advances776.96367.9567.25158.46131.30164.121.770.20
Intangible Assets------0.000.00
Other Assets9.111.952.123.022.020.030.000.00
Total Assets1,742.81978.03575.76603.13605.90487.18116.7044.23
Short Term Debt Incl. Current Port. of LT Debt13.7613.116.343.943.603.263.380.30
Accounts Payable4.015.997.084.334.004.373.282.06
Other Current Liabilities65.4448.6772.2763.0684.94102.9927.922.33
Total Current Liabilities83.2167.7785.6971.3492.54110.6234.574.69
Long Term Debt68.5074.6578.3313.3914.3614.7317.820.39
Provision for Risks Charges0.000.000.000.000.000.000.000.00
Other Liabilities11.440.0016.7728.2539.3677.9429.640.16
Total Liabilities163.15142.42180.79112.98146.27203.2982.035.24
Non-Equity Reserves0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00109.0873.43
Common Equity1,579.66835.62394.97490.15459.64283.89-74.41-34.44
Total Shareholders Equity1,579.66835.62394.97490.15459.64283.8934.6738.99
Accumulated Minority Interest0.000.000.000.000.000.000.000.00
Total Equity1,579.66835.62394.97490.15459.64283.8934.6738.99
Total Liabilities & Stockholders Equity1,742.81978.03575.76603.13605.90487.18116.7044.23
Book Value Per Share19.4212.887.118.918.926.38-1.67-0.77
Tangible Book Value Per Share19.4212.887.118.918.926.38-1.67-0.77
Full-Time Employees2381881871671417554-
Price to Book Ratio7.222.923.572.667.129.7110.84-
Return on Assets-22.89-28.81-24.93-25.61-18.34-15.10-51.26-
Return on Equity-25.78-36.38-33.21-32.60-26.96-28.62-111.98-
Return on Invested Capital-18.89-24.59-31.05-30.74-21.14-15.27-78.58-54.50
Quick Ratio10.477.534.735.884.882.732.698.92
Current Ratio10.477.534.735.884.882.732.698.92

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-349.43-311.35-223.86-146.96-154.81-100.22-45.59-41.25-21.47
Depreciation8.118.317.373.562.982.401.760.820.20
Other Funds (Non Cash)59.5354.8845.9537.8936.3730.807.091.641.09
Funds from Operations-281.79-248.16-170.53-105.51-115.46-67.02-36.74-38.78-20.17
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-5.7715.27-23.972.68-37.62-61.92124.8756.692.31
Cash from Operating Activities-287.56-232.89-194.50-102.83-153.09-128.9588.1317.91-17.86
Capital Expenditures-1.33-1.45-12.84-34.48-2.84-1.60-9.10-0.53-1.36
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments-414.23-519.61-391.24174.3723.36-98.24-413.49-15.950.00
Purchase of Investments-949.74-1,007.63-901.23-189.15-445.97-456.40-529.38-15.950.00
Sale Or Maturity of Investments535.50488.02509.99363.52469.33358.17115.890.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-415.56-521.06-404.08139.8920.52-99.83-422.59-16.49-1.36
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock965.69992.21610.434.27154.13251.53289.8235.2853.23
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock965.69992.21610.434.27154.13251.53289.8235.2853.23
Proceedsfrom Stock Options1,146.34930.59598.641.41150.97243.89289.6535.2153.23
Issuance or Reduction of Debt, Net-1.72-1.49-1.58-0.08-1.13-0.85-0.55-0.37-0.29
Change in Long Term Debt-1.72-1.49-1.58-0.08-1.13-0.85-0.55-0.37-0.29
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt-1.72-1.49-1.58-0.08-1.13-0.85-0.55-0.37-0.29
Net Financing Active Other Cash Flow0.000.000.000.000.00-0.400.000.000.00
Other Financing Activities Uses0.000.000.000.000.00-0.400.000.000.00
Cash from Financing Activities963.97990.71608.854.19153.00250.28289.2634.9152.93
Net Change in Cash260.85236.7610.2741.2520.4321.50-45.2036.3333.71
Free Cash Flow-288.89-234.34-207.34-137.31-155.92-130.5479.0317.37-19.22
Preferred Dividends (Cash Flow)-0.000.000.000.000.00-0.000.00
Price to Free Cash Flow------13.61--
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments971.21690.99650.93848.28505.68665.45
Short Term Receivables0.0020.000.000.000.0040.00
Inventories0.000.000.000.000.000.00
Other Current Assets27.3826.2826.5022.9422.6222.88
Total Current Assets998.59737.26677.43871.21528.30728.33
Net Property, Plant & Equipment78.6981.0783.3585.5388.0894.62
Total Investments and Advances680.88819.72900.53776.96478.84303.45
Other Assets9.117.387.709.116.834.67
Total Assets1,767.271,645.441,669.021,742.811,102.041,131.07
Short Term Debt Incl. Current Port. of LT Debt13.5813.7013.7313.7613.7413.67
Accounts Payable11.928.9212.844.015.515.78
Other Current Liabilities64.2248.7136.0765.4452.3368.09
Total Current Liabilities89.7271.3362.6483.2171.5887.54
Long Term Debt63.0264.8666.7468.5070.2572.05
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.0011.4413.960.00
Total Liabilities152.74136.19129.38163.15155.79159.59
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity1,614.531,509.261,539.641,579.66946.26971.48
Total Shareholders Equity1,614.531,509.261,539.641,579.66946.26971.48
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity1,614.531,509.261,539.641,579.66946.26971.48
Total Liabilities & Stockholders Equity1,767.271,645.441,669.021,742.811,102.041,131.07
Book Value Per Share18.9218.2318.7319.4213.1913.77
Tangible Book Value Per Share18.9218.2318.7319.4213.1913.77
Full-Time Employees285--238225218
Price to Book Ratio7.226.124.295.904.113.61
Return on Assets-24.36-21.58-24.35-22.89-27.62-28.15
Return on Equity-27.29-24.15-27.09-25.78-32.09-33.26
Return on Invested Capital-7.87-3.89-4.31-5.28-8.08-7.34
Quick Ratio11.1310.3410.8110.477.388.32
Current Ratio11.1310.3410.8110.477.388.32

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-132.00-61.21-69.23-86.98-82.17-76.61
Depreciation2.022.032.022.032.152.08
Other Funds (Non Cash)17.2316.6113.2812.4117.4713.29
Funds from Operations-112.75-42.57-53.94-72.54-62.56-61.23
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital34.83-11.49-34.915.7935.451.35
Cash from Operating Activities-77.91-54.06-88.84-66.75-27.11-59.88
Capital Expenditures-0.32-0.47-0.43-0.11-0.18-0.69
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments101.9520.52-142.41-394.29-235.1260.72
Purchase of Investments-60.66-114.66-276.27-498.16-367.56-58.25
Sale Or Maturity of Investments162.60135.17133.86103.87132.44118.97
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities101.6320.05-142.84-394.40-235.3060.02
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock226.0114.8619.19705.6339.93246.11
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock226.0114.8619.19705.6339.93246.11
Proceedsfrom Stock Options215.391.470.00929.47-237.29238.41
Issuance or Reduction of Debt, Net-0.44-0.44-0.42-0.42-0.42-0.38
Change in Long Term Debt-0.44-0.44-0.42-0.42-0.42-0.38
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt-0.44-0.44-0.42-0.42-0.42-0.38
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities225.5714.4218.77705.2239.51245.73
Net Change in Cash249.28-19.60-212.91244.07-222.90245.86
Free Cash Flow-78.23-54.54-89.27-66.85-27.29-60.58

Revenue breakdown

Biological Products, (No Diagnostic Substances)2024: 47.07M 2025: 39.21M
United States2024: 47.07M 2025: 39.21M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3010.96%8.4M76.7M770.25K
2026-10-1512.28%9.2M74.7M727.62K
2026-09-3013.29%9.9M74.6M684.97K
2026-09-1514.12%10.5M74.6M858.51K
2026-08-3113.90%10.4M74.6M852.63K
2026-08-1413.91%10.4M74.6M835.31K
2026-07-3113.53%10.0M73.7M791.70K
2026-07-1513.56%9.9M73.0M788.54K
2026-06-3013.90%10.1M73.0M767.74K
2026-06-1513.96%10.0M71.4M566.39K
2026-05-2914.17%10.1M71.3M578.82K
2026-05-1514.07%10.0M71.1M634.80K
2026-04-3013.67%9.7M70.9M695.14K
2026-04-1513.68%9.6M70.4M732.16K
2026-03-3114.88%10.4M69.9M773.54K
2026-03-1314.26%10.0M69.9M794.69K
2026-02-2714.70%10.3M69.9M1.00M
2026-02-1314.51%9.8M67.6M976.75K
2026-01-3013.99%9.4M66.9M970.67K
2026-01-1512.94%8.7M66.9M946.06K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call40.0093.5097.8081.804.8721.000.000.993-0.0840.004
call45.0088.5093.100.004.8410.000.000.948-0.7750.023
call50.0083.5088.100.004.4170.000.000.942-0.7720.025
call55.0078.5083.100.004.0370.000.000.936-0.7670.027
call60.0074.0078.600.003.6920.000.000.929-0.7590.029
call65.0069.0073.600.003.3760.000.000.922-0.7490.031
call70.0064.0068.3051.503.0401.000.000.915-0.7380.033
call75.0059.0063.0041.802.9642.000.000.907-0.7240.036
call80.0054.5058.0038.002.6998.000.000.898-0.7090.038
call85.0049.5054.4040.652.7140.000.000.883-0.7430.042
call90.0045.0048.5030.662.35228.000.000.872-0.7230.045
call95.0040.0043.8025.502.1907.000.000.859-0.6990.048
call10035.5039.3021.702.0687.000.000.844-0.6730.051
call10531.0034.8018.501.9348.000.000.827-0.6440.055
call11026.5030.3017.401.78912.000.000.800-0.6510.060
call11522.5025.8015.901.63416.000.000.768-0.6550.065
call12018.0022.0020.001.5681050.000.727-0.6650.071
call12514.0018.009.461.4471,1440.000.679-0.6560.076
call13010.5014.5011.901.36424.000.000.622-0.6250.081
call1357.0011.0010.861.24784.000.000.552-0.6080.084
call1405.009.008.261.2681,9520.000.482-0.6160.085
call1453.508.006.681.3693280.000.422-0.6350.084
call1502.157.005.031.4551.000.000.370-0.6520.080
call1551.556.003.901.4649.000.000.328-0.6310.077
call1600.655.503.551.5522.000.000.296-0.6390.074
call1650.004.903.001.6092.000.000.265-0.6270.070
call1700.004.901.351.7392.000.000.251-0.6590.068
call1750.004.902.471.86113.000.000.240-0.6880.067
call1800.004.900.901.9911.000.000.229-0.7160.065
call1850.004.901.352.0872.000.000.222-0.7380.064
call1900.004.901.352.1912.000.000.214-0.7600.062
call1950.304.901.352.28542.000.000.208-0.7800.062
call2000.004.900.002.3870.000.000.202-0.7990.060
put40.000.000.201.553.4216.000.00-0.007-0.0730.004
put45.000.004.900.106.1483.000.00-0.052-0.7700.023
put50.000.004.900.505.6225.000.00-0.058-0.7670.025
put55.000.004.900.755.1531.000.00-0.064-0.7610.027
put60.000.004.900.654.6987.000.00-0.071-0.7490.029
put65.000.104.900.504.35012.000.00-0.077-0.7440.031
put70.000.004.901.723.97420.000.00-0.085-0.7290.033
put75.000.004.902.603.65941.000.00-0.093-0.7170.036
put80.000.104.402.003.33979.001.00-0.102-0.7000.038
put85.000.004.902.563.1402.000.00-0.119-0.7280.042
put90.000.004.902.002.85836.000.00-0.130-0.7070.045
put95.000.004.905.702.6263520.00-0.140-0.6910.048
put1000.004.901.002.3733340.00-0.154-0.6650.051
put1050.104.903.002.1111450.00-0.172-0.6330.055
put1100.555.404.701.94438.000.00-0.200-0.6380.060
put1151.156.003.501.7927.000.00-0.232-0.6420.065
put1202.056.906.401.6706.000.00-0.273-0.6510.071
put1253.107.906.691.54216.000.00-0.321-0.6420.076
put1304.508.8010.951.38024.000.00-0.378-0.6110.081
put1356.0010.8010.401.3221.000.00-0.448-0.5930.084
put1408.9013.500.001.3440.000.00-0.518-0.6000.085
put14512.3016.800.001.3260.000.00-0.578-0.6190.084
put15016.0020.8021.321.39511.000.00-0.627-0.6310.081
put15520.0024.800.001.4360.000.00-0.673-0.6180.077
put16024.5029.3043.401.52211.000.00-0.705-0.6250.074
put16529.1033.800.001.6620.000.00-0.737-0.6120.070
put17033.6038.300.001.7200.000.00-0.750-0.6430.068
put17538.0042.800.001.7640.000.00-0.761-0.6710.066
put18042.6047.500.001.9100.000.00-0.771-0.6960.065
put18547.6052.500.001.9360.000.00-0.779-0.7190.063
put19052.1057.000.002.0380.000.00-0.786-0.7410.062
put19557.1062.000.002.0440.000.00-0.792-0.7600.061
put20062.1067.000.002.1360.000.00-0.798-0.7790.060

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-2910-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-10-298-KCurrent report2026-10-29SEC
2026-10-27SCHEDULE 13G/ASEC
2026-10-01144Filing for proposed sale of securities under Rule 144.SEC
2026-10-014Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-09-08SCHEDULE 13G/ASEC
2026-09-044Statement of changes in beneficial ownership of securities2026-09-04SEC
2026-09-04144Filing for proposed sale of securities under Rule 144.SEC
2026-09-02144Filing for proposed sale of securities under Rule 144.SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-13SCHEDULE 13G/ASEC
2026-08-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-058-KCurrent report2026-08-05SEC
2026-07-274Statement of changes in beneficial ownership of securities2026-07-27SEC
2026-07-273Initial statement of beneficial ownership of securities2026-07-27SEC
2026-07-278-KCurrent report2026-07-27SEC
2026-07-07144Filing for proposed sale of securities under Rule 144.SEC
2026-07-074Statement of changes in beneficial ownership of securities2026-07-07SEC
2026-07-02144Filing for proposed sale of securities under Rule 144.SEC
2026-07-024/A2026-06-26SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-01144Filing for proposed sale of securities under Rule 144.SEC
2026-06-30144Filing for proposed sale of securities under Rule 144.SEC
2026-06-304Statement of changes in beneficial ownership of securities2026-06-26SEC
2026-06-304Statement of changes in beneficial ownership of securities2026-06-26SEC
2026-06-29144Filing for proposed sale of securities under Rule 144.SEC
2026-06-29144Filing for proposed sale of securities under Rule 144.SEC
2026-06-26144Filing for proposed sale of securities under Rule 144.SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-10003.41M1
2026-0900744.30K1
2026-080000
2026-070015.56M3
2026-0600370.62M17
2026-05001.63M3
2026-04007.11M14
2026-030022.57M13
2026-02002.93M2
2026-0100373.52K1
2025-12172.50M140.04M8
2025-110000

Institutional holders

Manager% owned
FMR LLC15.12%
BAKER BROS. ADVISORS LP10.52%
Avoro Capital Advisors LLC9.09%
PRICE T ROWE ASSOCIATES INC /MD/8.65%
T. Rowe Price Investment Management, Inc.7.61%
BlackRock, Inc.6.73%
BVF INC/IL4.71%
WELLINGTON MANAGEMENT GROUP LLP4.47%
VANGUARD PORTFOLIO MANAGEMENT LLC3.64%
Siren, L.L.C.3.57%

Funds

Fund% owned
T. Rowe Price New Horizons Fund, Inc.2.74%
Fidelity Growth Company Fund2.70%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.54%
T. Rowe Price Capital Appreciation Fund2.49%
VANGUARD HEALTH CARE FUND2.18%
iShares Russell 2000 ETF1.95%
VANGUARD SMALL-CAP INDEX FUND1.84%
SMALLCAP World Fund Inc1.64%
State Street(R) SPDR(R) S&P(R) Biotech ETF1.55%
T. Rowe Price Health Sciences Fund, Inc.1.12%

OakChart. KYMR. Cached 15 minutes.